利伐沙班在心血管疾病中应用的临床进展  

Clinical Progress of Rivaroxaban in Cardiovascular Diseases

作　　者：林莹[1,2] 徐勇 郭新红[1] 刘昱圻[1] LIN Ying;XU Yong;GUO Xinhong;LIU Yuqi(Department of Cardiology,Chinese PLA General Hospital,Beijing 100853,China;Department of Cardiology,Hainan Hospital of Chinese PLA General Hospital,Sanya 572013,Hainan,China)

机构地区：[1]中国人民解放军总医院心血管内科,北京100853 [2]中国人民解放军总医院海南医院心血管内科,海南三亚572013

出　　处：《心血管病学进展》2020年第3期247-250,共4页Advances in Cardiovascular Diseases

摘　　要：利伐沙班与传统抗凝药物疗效相似,无需常规监测凝血功能,与药物和食物的相互作用较少,出血风险小。目前已被广泛用于骨科术后预防静脉血栓形成、深静脉血栓以及肺动脉栓塞、非瓣膜性心房颤动、急性冠脉综合征、外周动脉病等多种血栓栓塞性疾病的治疗及预防。Rivaroxaban has a similar efficacy to traditional anticoagulants and does not require monitoring coagulation indicators.Furthermore,it has little affected by drugs and food,and has little bleeding risk.At present,rivaroxaban has been widely used in prevention of venous thrombosis after orthopedic surgery and treatment of deep venous thrombosis,pulmonary embolism,nonvalvular atrial fibrillation,acute coronary syndrome,peripheral arterial disease and so on.

关 键 词：利伐沙班 抗凝 心血管疾病 有效性 安全性 

分 类 号：R54[医药卫生—心血管疾病]